Draft Evidence Review
Draft Evidence Review for Menopausal Hormone Therapy: Primary Prevention of Chronic Conditions
This opportunity for public comment expires on June 12, 2017 at 8:00 PM EST
Note: This is a Draft Evidence Review. This draft is distributed solely for the purpose of receiving public input. It has not been disseminated otherwise by the USPSTF. The final Evidence Review will be used to inform the USPSTF Recommendation Statement on this topic.
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Send Us Your Comments
In an effort to maintain a high level of transparency in our methods, we open our draft Evidence Reviews to a public comment period before we publish the final version.
Persons using assistive technology may not be able to fully access information in this PDF file. For assistance, contact Lisa Nicolella at (301) 427-1906 or email@example.com.
Internet Citation: Draft Evidence Review: Menopausal Hormone Therapy: Primary Prevention of Chronic Conditions . U.S. Preventive Services Task Force. May 2017.